An scFv antibody, whose full Chinese name is single-chain variable fragment, is a small engineered antibody fragment obtained through genetic engineering. An scFv consists of the variable region of an antibody's heavy chain (VH) and the variable region of its light chain (VL), connected by a synthetically designed short peptide linker. The variable regions are the "fingerprint recognition" domains of the antibody, determining which antigen the antibody can bind to specifically. The linker peptide is a flexible short chain of amino acids (most commonly (GGGGS)₃). Its role is like a tether, linking the VH and VL domains together, helping them form the correct three-dimensional structure to enable their function.

(i) Flexibility vs. Rigidity:
Flexible linkers, such as (GGGGS)ₙ, are commonly used. Glycine (G) has the smallest molecular weight with a side chain of only a hydrogen atom, providing excellent flexibility. Serine (S) enhances solubility and resists proteolytic degradation. This type of linker is long and flexible, reducing steric hindrance between the fused domains during refolding, thereby facilitating the correct folding of each structural domain of the fusion protein. Rigid linkers often contain amino acids like alanine (A), glutamic acid (E), and lysine (K), e.g., the (EAAAK)ₙ sequence, which can form a stable alpha-helical structure. These linkers are suitable for scenarios requiring fixed relative positions between two protein domains.

(ii) Linker Length Determines scFv Valency:
A length of approximately 15-20 amino acids is typically used to form monovalent scFv monomers. Shortening the linker to about 3-12 amino acids promotes the formation of dimers (Diabodies). Further reduction to 0-2 amino acids may lead to the formation of trimers (Tribodies) or other higher-order multimers.

(iii) Minimizing Interference:
The linker must have sufficient length and flexibility to prevent steric clash between the VH and VL domains during folding, ensuring they can form the correct antigen-binding pocket.

(iv) Selection Based on Functional Needs:
Choose standard-length flexible linkers (e.g., (GGGGS)₃) for simple monovalent binding. Consider shortened linkers to construct multimers (e.g., Diabodies) for pursuing higher avidity/multivalent binding. If the scFv is intended for fusion with other proteins (e.g., toxins, cytokines), the linker design must accommodate the folding and activity of both terminal proteins.

1. Primer Design
(i) The Critical Step:
Antibody variable region genes are highly diverse, but their framework regions are relatively conserved. It is impossible to design a single pair of specific primers for every possible variable region sequence. Therefore, degenerate primers are used – a mixture of primers capable of covering the vast majority of variable region gene families.
(ii) Target Sites:
-- VH genes: The upstream (forward) primer binds within the leader sequence or at the 5' end of the VH gene; the downstream (reverse) primer binds within the constant region (CH1) or the JH segment.
-- VL genes: The upstream primer binds within the leader sequence or at the 5' end of the VL gene; the downstream primer binds within the constant region (CL) or the JL segment.
(iii) Degeneracy:
To match minor variations among different germline genes, certain positions in the primer sequence are designed as mixed bases (e.g., R = A/G; Y = C/T; S = G/C; N = A/G/C/T).
(iv) Incorporating Restriction Sites:
Specific restriction enzyme sites (e.g., Sfi I, Not I, Xho I, Nco I) are added to the 5' ends of the primers for subsequent cloning into vectors. These sites are absent in the cDNA template, preventing digestion of the template.

2. PCR Amplification:
Use high-fidelity DNA polymerases (e.g., Phusion, KOD) for PCR to minimize mutations introduced during amplification. Set up separate PCR reactions for VH and VL. Verify the size of the amplified products (VH and VL fragments are typically ~400 bp each) by agarose gel electrophoresis and purify the target bands.

3. Assembling the scFv Gene by Overlap Extension PCR (SOE-PCR):
(i) First PCR (Overlap Extension): Mix the purified VH and VL fragments in a specific ratio and perform a few PCR cycles without the outer primers. During this step, VH and VL anneal via their complementary linker sequences and mutually extend, forming the full-length scFv sequence.
(ii) Second PCR (Amplification): Add primers targeting the outermost ends of the scFv gene to perform large-scale amplification, yielding abundant scFv gene product. Final Product: A full-length scFv gene with the structure VH - Linker - VL (or VL - Linker - VH).

(i) Targeted Therapy & Drug Delivery:
Conjugating scFvs to toxins, radionuclides, or drugs creates "biological missiles" for precise attacks on tumor cells.

(ii) CAR-T Cell Therapy:
The scFv is the core component of the antigen-binding domain in a CAR (Chimeric Antigen Receptor), responsible for recognizing specific targets on tumor cell surfaces.

(iii) Molecular Imaging Diagnostics:
Labeling scFvs with radionuclides allows precise localization of lesions using imaging techniques like PET/CT.

(iv) Basic Research Tools:
Used as intrabodies to neutralize specific protein functions inside cells, facilitating gene function studies.